ERBB2 and breast carcinoma: In 2011, the FDA also approved everolimus for patients with progressive neuroendocrine tumors of pancreatic origin (PNET) [38] and for the treatment of advanced hormone receptor-positive and HER2-negative breast cancers in combination with exemestane [39].